Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZTZMD
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
BAY-943
|
|||||
| Synonyms |
BAY 943; BAY943; VIP-943; IL3RA-KSPi-ADC
Click to Show/Hide
|
|||||
| Organization |
Bayer AG
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 2 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Clinical candidate
Hodgkin lymphoma [ICD11:2B30]
Clinical candidate
|
|||||
| Antibody Name |
TPP-9476
|
Antibody Info | ||||
| Antigen Name |
Interleukin-3 receptor subunit alpha (IL3RA)
|
Antigen Info | ||||
| Payload Name |
KSP inhibitor
|
Payload Info | ||||
| Therapeutic Target |
Kinesin-like protein KIF11 (KIF11)
|
Target Info | ||||
| Linker Name |
Protease cleavable linker
|
Linker Info | ||||
| Conjugate Type |
SPi was conjugated randomly to the lysine residues of a humanized derivative of the anti-IL3RA antibody 7G3, TPP-9476, via a novel protease-cleavable peptide linker.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.